Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome (RISAPS)
NCT03684564Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in antiphospholipid syndrome (APS), ischemic stroke, sponsored by University College London. Started Jul 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
antiphospholipid syndrome (APS)ischemic stroke
Beyond the preview
Go deeper on NCT03684564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684564.